Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms.

Cancer science - 1 Mar 2020

Yanagitani Noriko, Uchibori Ken, Koike Sumie, Tsukahara Mika, Kitazono Satoru, Yoshizawa Takahiro, Horiike Atsushi, Ohyanagi Fumiyoshi, Tambo Yuichi, Nishikawa Shingo, Fujita Naoya, Katayama Ryohei, Nishio Makoto

Abstract excerpt

The treatment for anaplastic lymphoma kinase (ALK)-positive lung cancer has been rapidly evolving since the introduction of several ALK tyrosine kinase inhibitors (ALK-TKI) in clinical practice. However, the acquired resistance to these drugs has become an important issue. In this study, we collected a total of 112 serial biopsy samples from 32 patients with ALK-positive lung cancer during multiple ALK-TKI...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminopyridines
Share to Anaplastic Lymphoma Kinase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carbazoles

Share to Crizotinib

Share to Lactams

Share to Lactams, Macrocyclic

Share to Piperidines

Share to Sulfones

Source

Open in PubMed Open full text

Identifiers

PMID: 31961053
DOI: 10.1111/cas.14314
PMCID: PMC7060465

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms.PMID 31961053Read ↗

Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical DataSemantic proximity Read ↗

Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.Semantic proximity Read ↗

Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.Semantic proximity Read ↗

Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review.Semantic proximity Read ↗

[Research progress of the resistance mechanism of non-small cell lung cancer to EGFR-TKIs].Semantic proximity Read ↗

Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells.Semantic proximity Read ↗

[Targeted Therapy and Mechanism of Drug Resistance in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor Gene Mutation].Semantic proximity Read ↗

[Molecular mechanisms of targeted drug resistance in lung cancer and its therapeutic strategy].Semantic proximity Read ↗

Acquired resistance in oncogene-addicted non-small-cell lung cancer.Semantic proximity Read ↗

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.Semantic proximity Read ↗

Analysis of Clinical Features and Treatment Strategies in Advanced Lung Adenocarcinoma Patients With Acquired ALK Fusion After Resistance of EGFR-TKIsSemantic proximity Read ↗

Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.